Live
BioPharma DiveCreate Medicines raises $122M to bolster in vivo CAR-T therapiesFierceBiotechBioAge CEO has big plans for 'multi-disease impact' of NLRP3 drug across cardio, ocular and CNSEndpoints NewsDrugmakers have to go through rigorous tests to get a lower tariff rateFierceBiotechBiopharma leaders rally behind Pazdur for FDA commissioner pick. But does he want the role?Promega BlogCharged Molecular Glues: The Molecular Trojan Horse That Slipped Past Biology’s Toughest BouncerClinical OMICsContact Lenses Show Promise for DepressionBioPharma DiveBiogen pushing tau drug forward despite Alzheimer’s study failureEndpoints NewsDegron, CREATE, TenNor raise capital; Cabaletta posts CAR-T dataEndpoints NewsAstraZeneca follows Merck with Phase 3 win in bladder cancerEndpoints NewsMacroGenics sells manufacturing arm; West Pharma discloses cybersecurity attackFierceBiotechCreate Medicines fashions $122M fundraise for in vivo CAR-T dreamsBioPharma DiveWith new data, Regenxbio to seek FDA approval of Duchenne gene therapy
FierceBiotech Mar 30, 2026

Scaling Radioligand Therapy: Expanding the Impact of Theranostics

Scaling Radioligand Therapy: Expanding the Impact of Theranostics

Original
Body unavailable. Use the original source.